Clinical trials: Inhibitors
Non-small Cell Lung Cancer
Aprepitant vs. Desloratadine in EGFR-TKIs Related Pruritus Treatment
Study hypothesis is that aprepitant is more effective than desloratadine in relieving pruritus caused by EGFR TKIs. Primary endpoint is the effective rate of pruritus, effective treatment defined as visual analogue scale (VAS)…
- Trial name
- EGFR-TKIs (NCT02646020)
- Testing
- Aprepitant, Desloratadine
- Where
- China
- Volunteers
- 138 people
- Sponsor
- Sun Yat-sen University
Kidney Neoplasm
Impact of Chronic Renal Failure on Plasma Exposure of Kinase Inhibitors in Patients Treated for Metastatic Kidney Cancer
The study of the blood concentration of ITK what are pazopanib and cabozantinib at 1 month and 3 months from the start of treatment will allow to evaluate the impact of renal failure on their efficacy and toxicity in patients…
- Trial name
- IREKI (NCT04823923)
- Testing
- blood sampling for ITK dosage
- Where
- 5 sites in France
- Volunteers
- 60 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Metastatic Breast Cancer
Letrozole in the Treatment of 1st and 2nd Line Hormone Receptor Positive Breast Cancer: Pre-therapeutic Risk Assessment
The course of the disease in female patients with metastatic mammary carcinoma can vary greatly. In this connection, the individual prognosis depends on a complex interaction of tumor- and patient-related factors.
- Trial name
- NCT00241046
- Testing
- Letrozole
- Volunteers
- 13 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer Female, Osteoporosis
Health and QoL in Oncological Patients: Management of Bone Pathology in Italian Citbl Population
Studying the current state of the clinical approaches to bone diseases in breast cancer patients treated with adjuvant and/or hormone therapy
- Trial name
- NCT04055805
- Testing
- Observational Analysis
- Where
- Italy
- Volunteers
- 700 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Metastatic Cervical Cancer, Persistent Cervical Cancer
PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer
This is a randomized trial evaluating the results of using of PD-1 and PD-L1 immune checkpoint inhibitors combined with chemotherapy, with or without bevacizumab, in patients with metastatic, persistent, and recurrent cervical…
- Conditions
- Metastatic Cervical Cancer, Persistent Cervical Cancer, Recurrent Cervical Cancer
- Trial name
- NCT07472153
- Testing
- PD-1 antibody, PD-L1 antibody, Chemotherapy and bevacizumab (CT-BEV)
- Where
- Belarus
- Volunteers
- 120 people
- Sponsor
- N.N. Alexandrov National Cancer Centre
Rheumatoid Arthritis
Comparative Study of Janus Kinase (JAK) Inhibitors Vs Tumor Necrosis Factor (TNF) Inhibitors in Rheumatoid Arthritis
Rheumatoid arthritis is a systemic autoimmune disease characterized by inflammatory synovitis and progressive joint destruction, which are associated with severe disability and increased mortality.
- Trial name
- NCT05567380
- Testing
- Observation
- Volunteers
- 150 people
- Sponsor
- Sohag University
Hemophilia A With Inhibitor, Hemophilia B With Inhibitor
SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors
Phase IV multi-center, US-centric, open-label, safety study enrolling participants with Hemophilia A or B with inhibitors, 12 years of age and older, who are either on long term prophylactic treatment (e.g., emicizumab) at risk…
- Trial name
- NCT04647227
- Testing
- coagulation factor VIIa [recombinant]-jncw
- Where
- 21 sites in United States
- Volunteers
- 55 people
- Sponsor
- American Thrombosis and Hemostasis Network
Ovarian Cancer
Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer
Immunotherapy with immune checkpoint inhibitors, including pembrolizumab, have emerged as a promising option in several solid cancers with durable effect and low toxicity profile.
- Trial name
- NCT05467670
- Testing
- Pembrolizumab, ALX148, Doxorubicin
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Alexander B Olawaiye, MD
HIV-infected Patient Kidney Transplant Recipient
Pharmacokinetics of Calcineurin & mTOR Inhibitors in HIV-1 Infected Kidney Transplant Recipients After Switch to BIC/FTC/TAF
Chronic kidney disease (CKD) is a critical comorbidity for patients living with HIV (PLWH), with an estimated prevalence between 2.4 and 17%, leading to end-stage renal disease 3 to 6 fold more than non-HIV population.
- Trial name
- KINETIK (NCT04993872)
- Testing
- Biktarvy Tab
- Where
- 2 sites in France
- Volunteers
- 5 people
- Sponsor
- Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba
Ovarian Cancer
Combined Program of Supervised Physical Exercise and Nutritional Counseling in Ovarian Cancer Patients on Frontline Maintenance Treatment With PARP Inhibitors
Patients will be recruited in the 4 participating sites and will sign the informed consent If they agree to participate. It is planned to include 32 patients with ovarian cancer on maintenance PARPi after response to first-line…
- Trial name
- NCT06139783
- Testing
- Exercise and dietary recommendations
- Where
- 4 sites in Spain
- Volunteers
- 32 people
- Sponsor
- Oncare Madrid
Chronic Myeloid Leukemia, Pregnancy
Observational Study of Conception/Pregnancy in Adult Patients With CML Treated With Tyrosine Kinase Inhibitors
The objective of this study is to acquire more information about what we are doing during pregnancy in CML patients, in order to possibly establish in the future a consensus on the management of patients receiving TKIs who wants…
- Trial name
- CML1012 (NCT01752062)
- Where
- 52 sites in Italy
- Volunteers
- 148 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors
This is a phase II, open label, prospective, single-arm study evaluating the efficacy and safety of selinexor in patients with PMF or secondary MF (PPV-MF or PET-MF) who are refractory or intolerant to ruxolitinib and/or any…
- Conditions
- Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Post-polycythemia Vera Myelofibrosis
- Trial name
- ESSENTIAL (NCT03627403)
- Testing
- Selinexor
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Utah
Hemophilia
Global Haemostatic Methods Following Administration of Bypassing Agents to Patients With Haemophilia With Inhibitors
Background The treatment of haemophilia A and B has been revolutionized by the use of factor concentrate, both as prophylaxis and to treat bleeding episodes (on-demand treatment).
- Trial name
- NCT02453542
- Where
- Sweden
- Volunteers
- 20 people
- Sponsor
- Karolinska Institutet
Platelet Aggregation Inhibitors
Maintenance Of aNtiplatElet Therapy in Patients With Coronary Stenting Undergoing Surgery (MONET BRIDGE)
The MONET BRIDGE study is designed to assess the use of cangrelor as a platelet-inhibiting bridge for patients who discontinue DAPT before cardiac and non cardiac surgery within 12 months from coronary stent implantation.
- Trial name
- NCT03862651
- Testing
- Cangrelor
- Volunteers
- 140 people
- Sponsor
- Ospedale Santa Croce-Carle Cuneo
HIV Infections
Combination Latency Reversal With High Dose Disulfiram Plus Vorinostat in HIV-infected Individuals on ART
Antiretroviral therapy (ART) dramatically reduces Human Immunodeficiency Virus (HIV) replication leading to restoration of immune function and a near normal life expectancy, but treatment is lifelong and there is no cure.
- Trial name
- NCT03198559
- Testing
- Disulfiram, (National Drug Code) NDC 0378-4141-01, Vorinostat, NDC 00006-0568-40
- Where
- Australia
- Volunteers
- 5 people
- Sponsor
- University of Melbourne
Acute Ischemic Stroke
Efficacy and Safety of PCSK9 Inhibitors in Patients With Large-Artery Atherosclerosis (LAA) Ischemic Stroke
This prospective multicenter cohort study aims to evaluate the effectiveness and safety of early PCSK9 inhibitor therapy in patients with large-artery atherosclerotic ischemic stroke.
- Trial name
- NCT07540741
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- First Affiliated Hospital of Harbin Medical University
Diabetes Mellitus, Prostatic Hyperplasia
SGLT Inhibitors Versus DDP4 Inhibitors and Prostate in Patient With Diabetes
The study aims to compare the effect of two different classes of anti- diabetes medications on prostate volume and symptoms in elderly patients with diabetes mellitus
- Trial name
- NCT06148259
- Testing
- International prostate symptom score, Assessment of prostate volume, Pittsburgh sleep quality Index
- Where
- 2 sites in Egypt
- Volunteers
- 57 people
- Sponsor
- Kasr El Aini Hospital
Fabry Disease, Proteinuria
The Fabrazyme® and Arbs and ACE Inhibitor Treatment (FAACET) Study
The primary hypothesis is that titration of ACE inhibitor and Angiotensin Receptor Blockers (ARBs)to reduce urine protein excretion to < 500 mg per day in Fabry Patients receiving agalsidase beta therapy at 1 mg/kg every two…
- Trial name
- FAACET (NCT00446862)
- Testing
- enalapril and other angiotensin converting enzyme inhibitors; losartan and other angiotensin receptor blockers
- Where
- 6 sites in United States, Slovenia
- Volunteers
- 36 people
- Sponsor
- University of Alabama at Birmingham
HIV-1-infection
Etravirine Plus 2 Analogs in HIV-infected Patients
The purpose of this study is to evaluate the virological and clinical efficacy of etravirine plus 2 active nucleos(t)ide reverse-transcriptase inhibitors (NRTIs) in HIV-infected patients.
- Trial name
- NCT01437241
- Where
- 11 sites in Spain
- Volunteers
- 175 people
- Sponsor
- Hospitales Universitarios Virgen del Rocío
Deep Venous Thrombosis, Upper Extremity Deep Venous Thrombosis
Apixaban for Routine Management of Upper Extremity Deep Venous Thrombosis
This study will assess the safety and effectiveness of a drug called apixaban for the treatment of upper extremity deep vein thrombosis (UEDVT) and clinically important bleeding.
- Conditions
- Deep Venous Thrombosis, Upper Extremity Deep Venous Thrombosis, Thrombus, Venous Thromboembolism
- Trial name
- ARM-DVT (NCT02945280)
- Testing
- apixaban
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Intermountain Health Care, Inc.